Presenter: Farzad Kamyar MD, MBA, Director of Collaborative Care MOTHER program at High-Risk Pregnancy Center, Psychiatry and Addiction Medicine
Online CME Credit
Fee: $50.00
Provides 1.00 hour(s) of CE/CME credit (Presented on July 14, 2021; Reviewed June 20, 2023; Expires August 6, 2024)
This series will provide information surrounding reproductive health (pregnancy) and substance use. It aims to summarize best practices, guidelines, and protocols for medical professionals involved in the care of pregnant patients with Substance Use Disorder (SUD) or more specifically Opioid Use Disorder (OUD). The goal is to help improve the identification and treatment of SUD, identification, and treatment for the infant(s), reproductive planning, and care coordination to decrease parental and/or neonatal complications before, during, and/or after delivery.
This series is directed toward anyone who interfaces with pregnant and non-pregnant patients of reproductive age. Specifically, medical professionals who are licensed in the state of Nevada, include physicians, nurse practitioners, physician assistants, registered nurses, licensed midwives, lactation consultants, licensed clinical social workers, and case managers. However, this does not preclude others such as government agencies, specialty offices, and first responders from using this as a resource or in various clinical situations where contact with a pregnant patient is made.
Following participation in this course, participants should be able to:
Instructions for receiving CME/CE credit:
For questions concerning the online evaluation or your certificate, please contact our office at (775) 784-4791 or email us at cme@med.unr.edu.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and the Center for the Application of Substance Abuse Technologies (CASAT). The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
The University of Nevada, Reno School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 1.00 hour(s) of nursing continuing education credit.
This program provides 1 credit toward the Nevada State Board of Medical Examiners' requirement for 2 hours of training related to ethics, pain management, or addiction care during each licensure period.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that they do not have financial relationships with ineligible companies related to the content of this activity.
NIDA. Preface. National Institute on Drug Abuse website. https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/preface. July 20, 2020 Accessed June 2, 2021.ASAM. Definition of Addiction. https://www.asam.org/Quality-Science/definition-of-addiction. September 15, 2019.
El-Mohandes, A., Herman, A. A., Nabil El-Khorazaty, M., Katta, P. S., White, D., & Grylack, L. (2003). Prenatal care reduces theimpact of illicit drug use on perinatal outcomes.Journal of perinatology : official journal of the California Perinatal Association,23(5), 354-360. https://doi.org/10.1038/sj.jp.7210933
Schif DM, Nielsen T, Terplan M, Hood M, Bernson D, Diop H, Bharel M, Wilens TE, LaRochelle M, Walley AY, Land T. Fatal and Nonfatal Overdose Among Pregnant and Postpartum Women in Massachusetts. Obstet Gynecol. 2018 Aug;132(2):466-474. doi: 10.1097/AOG.0000000000002734. PMID: 29995730; PMCID: PMC6060005.
Jacobs AA, Cangiano M. Medication-Assisted Treatment Considerations for Women with Opiate Addiction Disorders. Prim Care. 2018 Dec;45(4):731-742. doi: 10.1016/j.pop.2018.08.002. Epub 2018 Oct 5. PMID: 30401353.
McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000 Oct 4;284(13):1689-95. doi: 10.1001/jama.284.13.1689. PMID: 11015800.
Jones HE, Kaltenbach K, Heil SH, Stine SM, Coyle MG, Arria AM, O'Grady KE, Selby P, Martin PR, Fischer G. Neonatal abstinencesyndrome after methadone or buprenorphine exposure. N Engl J Med. 2010 Dec 9;363(24):2320-31. doi: 10.1056/NEJMoa1005359. PMID: 21142534; PMCID: PMC3073631.
Naloxone for opioid safety. A Nevada provider's guide to prescribing naloxone to patients who use opioids. Nevada Division ofPublic and Behavioral Health. http://dpbh.nv.gov/uploadedFiles/dpbhnvgov/content/Resources/opioids/naloxone_toolkit_ color.pdf
Substance Abuse and Mental Health Services Administration. Special Circumstances for Providing Buprenorphine. May 2020. https://www.samhsa.gov/ medication-assisted-treatment/legislation-regulations-guidelines/special
SAMHSA. FAQ About New Buprenorphine Practice Guidelines. https://www.samhsa.gov/medication-assisted-treatment/practitioner-resources/faqs28